anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Obesity has become a global public health issue and is closely related to bowel habits. The Weight-Adjusted-Waist Index (WWI), a new indicator of obesity, provides a more accurate assessment of central obesity. This study aims to investigate the relationship between WWI and bowel habits. The 2005-2010 National Health and Nutrition Examination Survey (NHANES) dataset was used for the cross-sectional survey. Bowel habits were defined by self-report. Multiple logistic regression models were used to test the linear association of WWI with chronic diarrhea and constipation. Fitted smoothed curves and threshold effects analysis were used to characterize nonlinear relationships. Subgroup analyses and interaction tests were used to determine the heterogeneity and stability of the study. This population-based study included 14,238 adults (≥ 20 years). After adjusting for covariates, there was a significant positive association between WWI and chronic diarrhea (OR [95% CI] 1.27 [1.14, 1.41]). There was a non-linear association between WWI and chronic constipation, and we found a breakpoint of 9.77, with a positive correlation on the left side of the breakpoint and no statistical significance on the right side. Subgroup analyses and interaction tests showed stable and consistent results between WWI and bowel habits across the stratification factors. Elevated levels of WWI are associated with an increased risk of chronic diarrhea. A range of WWI < 9.77 is associated with an increased risk of chronic constipation. WWI is a stable valid indicator for assessing intestinal health in U.S. adults, and we should be mindful of the importance of maintaining good levels of body fat in our daily lives to maintain healthy bowel habits.
FIELD: medicine, gastroenterology. SUBSTANCE: invention relates to method of treatment of gastroduodenitis and ulcers associated with Helicobacter pylori. For this aim the preparation "Makmirror" is included additionally to the treatment complex comprising of H 2 -histamine antagonist or inhibitor of proton pump and antibiotic also. Method provides enhancement of effectiveness of treatment based on enhancement of antibacterial activity. EFFECT: improved and enhanced method of treatment. 2 ex
The invention relates to a stripping type film used for safety protection, and a preparation method thereof. The stripping type film comprises following ingredients, by weight, 8 to 20% of polyvinyl alcohol, 1 to 20% of polyethylene glycol, 0.5 to 15% of a thickening agent or 10 to 20% of an emulsifier, 0.1 to 5% of a surfactant, 0.1 to 10% of a plant essential oil, 0.1 to 1% of an antiseptic, 2 to 20% of a polyol hydrophilic agent, and 40 to 80% of water. Weight ratio of the ingredients is preferably 12.5:15:6 or 15:0.5:2:0.3:14:49.7 or 40.7. According to the preparation method, the mixture, used for forming the stripping type film, is an oil-in-water type emulsifier prepared by emulsification of film-forming material polyvinyl alcohol, the polyol, water, and the surfactant used for the plant essential oil, and the mixture is a colourless or light yellow transparent emulsion. pH value of the mixture ranges from 6.0 to 7.0, and the mixture can be stably stored for 12 months under normal conditions. If skin is coated with the mixture, 1 minute later, the stripping type film is formed after drying. The stripping type film is easy for stripping; no skin stimulation or adverse reaction is caused; and the stripping type film is capable of resisting bacteria penetrating, and increasing skin elasticity and antioxidation ability of skin, and is suitable for labor protection of people who use the stripping type film.
Asthma is the most common long-term disease among children. Each year, most children with asthma will have at least one asthma exacerbation, experience asthma symptoms on approximately 100 days, and miss 4 days of school because of asthma. Surveys of primary care physicians (PCPs) and asthma patients have indicated that asthma care is episodic, effective asthma controller medications are underused, and few PCPs provide self-management education or support for parents of children with asthma. Previous research showed that when an asthma coach worked with parents of children from low-income, urban neighborhoods, there were multiple benefits: improved self-management behaviors, reduced asthma hospitalizations, and improved rates of follow-up with a PCP after an emergency department visit for asthma symptoms. In this study, researchers will evaluate the effectiveness of an asthma coach program in a larger, general asthma population. Trained asthma coaches will work with parents of children with asthma to provide education about the goals of asthma care, and they will encourage and facilitate an active partnership between the family and PCP to enhance asthma care and improve self-management behaviors. Study researchers will then evaluate the effectiveness of this program at improving asthma control and quality of life among children with asthma. The cost effectiveness of the program will also be analyzed.

This study will enroll pediatricians and parents of children between 5 and 12 years old who have persistent asthma. Pediatricians will be randomly assigned to either the asthma coach program or usual care. All pediatricians will receive access to the Education in Quality Improvement for Pediatric Practice (eQIPP) module for asthma care provided by the American Academy of Pediatrics. They will also receive articles about effective doctor-parent communication on asthma and asthma billing practices. In addition, pediatricians taking part in the asthma coach program will attend two meetings to learn about asthma coaching and how the program can be implemented into their practice. For 12 months, an asthma coach will work directly with the parents of children who see doctors participating in the asthma coaching group. Telephone calls with the asthma coach will be arranged at times convenient for the parent and will occur anywhere between once a week to once a month. At Months 12 and 24, about 40 parents of children in each pediatrician's practice will participate in telephone interviews and their children's medical charts will be reviewed to assess asthma control, asthma-related quality of life factors, and urgent care events.
PURPOSE:To provide an auxiliary agent containing a specific mitrotriazole derivative as an active component, to be used in combination with a carcinostatic agent and effective for mitigating the strong cytotoxicity of the carcinostatic agent and promoting the chemotherapeutic effect of the carcinostatic agent. CONSTITUTION:The objective agent for alleviating the side effect and promoting the carcinostatic action of a cytotoxic carcinostatic agent contains a nitrotriazole derivative of formula (l is 1-3; n is 0-3; n is 0-3) such as 2-(3'-nitro-l'-triazolyl)acetic acid amide as an active component. The compound of formula can be administered to human at a rate of about 1-2g/dose without developing side effects. The active amount of the compound of formula depends upon the kind and the amount of the cytotoxic carcinostatic agent to be used in combination and is about 1/10 to 3 times the dose of the carcinostatic agent. The side effect of the carcinostatic agent on the digestive organ (e.g. loss of weight) can be alleviated and the carcinostatic action can remarkably be promoted by the use of the auxiliary agent in combination with the carcinostatic agent.
In this opinion article, we discuss potential connections between sleep disturbances observed in Alzheimer's disease (AD) and Parkinson's disease (PD) and the dysregulation of lipids in the brain. Research using Drosophila has highlighted the role of glial-mediated lipid metabolism in sleep and diurnal rhythms. Relevant to AD, the formation of lipid droplets in glia, which occurs in response to elevated neuronal reactive oxygen species (ROS), is required for sleep. In disease models, this process is disrupted, arguing a connection to sleep dysregulation. Relevant to PD, the degradation of neuronally synthesized glucosylceramides by glia requires glucocerebrosidase (GBA, a PD-associated risk factor) and this regulates sleep. Loss of GBA in glia causes an accumulation of glucosylceramides and neurodegeneration. Overall, research primarily using Drosophila has highlighted how dysregulation of glial lipid metabolism may underlie sleep disturbances in neurodegenerative diseases.
General:A yellowish tinge of the skin or sclera may indicate accumulation due to impaired renal excretion and the need to discontinue therapy. The decline in renal function associated with advanced age should be kept in mind. While our product does not contain Sulfur, it has been indicated to exhibit in rare circumstances a sulfur-type reaction. Use of this product in patients sensitive to sulfur should be done so under the supervision of a Physician. 

NOTE: Patients should be informed that Phenazopyridine HCl produces a reddish-orange discoloration of the urine and may stain fabric. Staining of contact lenses has been reported. 

Laboratory Test Interaction:Due to its properties as an azo dye, Phenazopyridine HCl may interfere with urinalysis based on spectrometry or color reactions. 

Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term administration of Phenazopyridine HCl has induced neoplasia in rats (large intestine) and mice (liver).   
Although no association between Phenazopyridine HCl and human neoplasia has been reported, adequate epidemiological studies along these lines have not been conducted. 

Pregnancy Category B:Reproduction studies have been performed in rats at doses up to 50 mg/kg/day and have revealed no evidence of impaired fertility or harm to the fetus due to Phenazopyridine HCl. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. 

Nursing mothers:No information is available on the appearance of Phenazopyridine HCl, or its metabolites in human milk.
BACKGROUND: Oral cavity cancers requiring excision of the oral commissure and free flap reconstruction often requires commissuroplasty to manage oral incontinence. We aimed to evaluate the implications of primary versus delayed commissuroplasty on drooling, and interincisal distance outcomes in this cohort.
METHODS: A retrospective query of head and neck cancer patients operated by a single surgeon from 2017 to 2020 was performed. Patients were included if they underwent free flap reconstruction of the oral commissure, had an immediate or delayed commissuroplasty, and had 2 years of follow-up data including Thomas-Stonell and Greenberg drooling rating scales and interincisal distance measurements.
RESULTS: Thirty-five patients were included in the review. Twelve patients received immediate commissuroplasty and 23 patients had delayed commissuroplasty. Interincisal distance was similar at baseline, although significantly varied between immediate and delayed commissuroplasty groups at 1 month and 2 years postoperative. Drooling scores were significantly elevated in the group treated with delayed commissuroplasty, but eventually normalized after staged surgery and follow-up. Patients treated with adjunct radiation therapy had lower interincisal distance than patients who did not have radiation.
CONCLUSION: Delayed commissuroplasty increased interincisal distance and normalize drooling in patients who required full-thickness excision of the buccal mucosa and oral commissure and free tissue reconstruction. The presented data can help to educate patients on expected postoperative outcomes and likely advocates for a second-stage procedure after completion of adjunct radiotherapy to achieve optimal commissural placement and oral competence.
In addition to TD, metoclopramide may cause other extrapyramidal symptoms (EPS), parkinsonian symptoms, and motor restlessness. Advise patients to seek immediate medical attention if such symptoms occur and to discontinue Reglan.

•
    Extrapyramidal symptoms (EPS), such as acute dystonic reactions, occurred in patients treated with metoclopramide dosages of 30 mg to 40 mg daily. Such reactions occurred more frequently in adults less than 30 years of age and at higher than recommended dosages. EPS occurred more frequently in pediatric patients compared to adults (Reglan is not approved for use in pediatric patients). Symptoms can occur in the first 24 to 48 hours after starting metoclopramide. Symptoms included involuntary movements of limbs and facial grimacing, torticollis, oculogyric crisis, rhythmic protrusion of tongue, bulbar type of speech, trismus, or dystonic reactions resembling tetanus. Rarely, dystonic reactions were present as stridor and dyspnea, possibly due to laryngospasm. Diphenhydramine hydrochloride or benztropine mesylate may be used to treat these adverse reactions. Avoid Reglan in patients receiving other drugs that can cause EPS (e.g., antipsychotics).
•
    Parkinsonian symptoms (bradykinesia, tremor, cogwheel rigidity, mask-like facies) have occurred after starting metoclopramide, more commonly within the first 6 months, but also after longer periods. Symptoms generally have subsided within 2 to 3 months after discontinuation of Reglan. Avoid Reglan in patients with Parkinson’s disease and other patients being treated with antiparkinsonian drugs due to potential exacerbation of symptoms. Avoid treatment with Reglan for more than 12 weeks [see Dosage and Administration (2.2, 2.3), Warnings and Precautions (5.1)].
•
    Motor restlessness (akathisia) has developed and consisted of feelings of anxiety, agitation, jitteriness, and insomnia, as well as inability to sit still, pacing, and foot tapping. If symptoms resolve, consider restarting at a lower dosage.
INTRODUCTION: Micro- and macrovascular complications are common among persons with type 2 diabetes. Recently there has been growing interest to investigate the potential of circulating small non-coding RNAs (sncRNAs) as contributors to the development of diabetic complications. In this study we investigate to what extent circulating sncRNAs levels associate with prevalent diabetic kidney disease (DKD) in persons with type 2 diabetes.
METHODS: Plasma sncRNAs levels were determined using small RNA-seq, allowing detection of miRNAs, snoRNAs, piRNAs, tRNA fragments, and various other sncRNA classes. We tested for differentially expressed sncRNAs in persons with type 2 diabetes, with DKD (n = 69) or without DKD (n = 405). In secondary analyses, we also tested the association with eGFR, albuminuria (UACR), and the plasma proteome.
RESULTS: In total seven sncRNAs were negatively associated with prevalent DKD (all PFDR ≤ 0.05). Including one microRNA (miR-143-5p), five snoRNAs (U8, SNORD118, SNORD24, SNORD107, SNORD87) and a piRNA (piR-019825 | DQ597218). Proteomic analyses showed that the seven sncRNAs, and especially the piRNA piR-019825, were associated with plasma levels of 24 proteins of which several have known associations with kidney function including TNF sR-I (TNFRFS1A), DAN (NBL1) and cystatin C (CST3).
CONCLUSION: We have identified novel small non-coding RNAs, primarily from classes other than microRNAs, that are associated with diabetic kidney disease. Our results show that the involvement of small non-coding RNAs in DKD goes beyond the already known microRNAs and also involves other classes of sncRNA, in particular snoRNAs and the piRNA piR-019825, that have never been studied before in relation to kidney function.
A system and method for development and management of a trusted support network for an at-risk person. The system provides a computerized interface providing the at-risk person with both synchronous and asynchronous support, to ensure that the at-risk person is adequately supported at critical times to lessen the risk of harm. The system provides for training of laypersons, so that a layperson can provide effective support and intervention to avert adverse outcomes for such an at-risk person. Further, the system provides for communication among multiple members of a support team. Further still, the system provides for delivery of not only person-to-person supportive communications, but also automated composition and/or delivery of supportive communications. Accordingly, the system can cause display of notices/notifications/alerts and/or placing of telephone calls, sending of text messages, etc. and provide communications in lieu of, or in addition to, those from a supporter.
The research study is being conducted to better understand the effects of ketosis on brain functioning and the acute effects of alcohol. Healthy participants will undergo three randomly assigned dietary interventions, each lasting three days, followed by a study lab visit day on day 4. The three interventions are: (1) Eat a ketogenic diet for 3 days, (2) eat a control diet for 3 days with a ketone supplement drink, and (3) eat a control diet for 3 days. The dietary interventions will be spaced 1 week apart. The ketone supplement drink (Kenetik, Vitanav inc, Washington DC) is a dietary supplement that has been extensively studied in humans and is designated by the FDA as Generally Recognized as Safe (GRAS). Its use in this study is experimental. On the day of the 3 labs visits days, magnetic resonance imaging (MRI) will be used to study the brain. Specifically, levels of nicotinamide adenine dinucleotide (NAD) (a coenzyme that is important for energy metabolism), lactate (a metabolite produced during energy metabolism), and neurotransmitters glutamate and GABA. Following the scans, participants will be provided a dose of alcohol that will elevate participants breath alcohol levels to approximately 0.08% to measure the acute effects of alcohol.
Hair cleanser that provides hair treated therewith with advantageous characteristics and in particular promotes the penetration of bioactive materials into the scalp, comprises the following in a cosmetically acceptable substrate – relative to weight - (a) 0.001 to 10 wt.-% of at least one cationic terpolymer that is composed of i. at least one vinyl imidazole monomer, ii. at least one vinyl pyrrolidone monomer and iii. poly(dimethyldiallylammonium chloride) and (b) at least one bioactive material selected from i. L-carnitine and/or a physiologically compatible derivative and/or salt of carnitine; ii. 2-furanones and/or physiologically compatible derivatives thereof; iii. taurine and/or a physiologically compatible derivative and/or salt of taurine; iv. a vitamin of group B 1 , B 2 , B 3 , B 6 , B 7 , B 9 , B 12  and/or a physiologically compatible derivative and/or salt of said vitamins; v. purine and/or physiologically compatible derivatives thereof.
Serious rash requiring hospitalization and discontinuation of treatment has been reported in association with the use of modafinil.

In clinical trials of modafinil, the incidence of rash resulting in discontinuation was approximately 0.8% (13 per 1,585) in pediatric patients (age <17 years); these rashes included 1 case of possible Stevens-Johnson Syndrome (SJS) and 1 case of apparent multi-organ hypersensitivity reaction. Several of the cases were associated with fever and other abnormalities (e.g., vomiting, leukopenia). The median time to rash that resulted in discontinuation was 13 days. No such cases were observed among 380 pediatric patients who received placebo. PROVIGIL is not approved for use in pediatric patients for any indication [see Use in Specific Populations (8.4)]. 

Rare cases of serious or life-threatening rash, including SJS, Toxic Epidermal Necrolysis (TEN), and Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) have been reported in adults and children in worldwide postmarketing experience. The reporting rate of TEN and SJS associated with modafinil use, which is generally accepted to be an underestimate due to underreporting, exceeds the background incidence rate. Estimates of the background incidence rate for these serious skin reactions in the general population range between 1 to 2 cases per million-person years. 

There are no factors that are known to predict the risk of occurrence or the severity of rash associated with PROVIGIL. Nearly all cases of serious rash associated with modafinil occurred within 1 to 5 weeks after treatment initiation. However, isolated cases have been reported after prolonged treatment (e.g., 3 months). Accordingly, duration of therapy cannot be relied upon as a means to predict the potential risk heralded by the first appearance of a rash. 

Although benign rashes also occur with PROVIGIL, it is not possible to reliably predict which rashes will prove to be serious. Accordingly, PROVIGIL should be discontinued at the first sign of rash, unless the rash is clearly not drug-related. Discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.
Immediately after epidural placement, patient will be placed in a left tilt position with her hip on a wedge. She will remain in this position for approximately 40 minutes.
Patients will receive a 15-day lead-in of liposomal doxorubicin, followed by liposomal doxorubicin on Day 1 and 10mg/kg avelumab over 60 minutes on Day 1 and Day 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
PURPOSE:To provide the subject derivative containing the octapeptide unit of formula Glu-I le-Leu-Asp-Val-Pro-Ser-Thr, having activity to inhibit the adhesion of animal cell and the coagulation and cohesion of platelet and useful for suppressing cancer metastasis. CONSTITUTION:The objective peptide derivative of formula II ((n) is 1-3) or its salt can be produced by reacting a dialkyl (diacyl) glycerol (e.g. 1,2- dihexadecylglycerol) with a cyclic acid anhydride (e.g. succinic anhydride) in an organic solvent capable of dissolving the above components (e.g. methylene chloride) in the presence of a base at room temperature to obtain a dialkyl (diacyl) glycerol derivative of formula I (R<1> and R<2> are H, 8-24C acyl or alkyl;(m)is 1-5), separately preparing a protected peptide by successively bonding protected amino acids according to the amino acid sequence of the objective peptide in the presence of a condensation agent and condensing the above compound with the protected peptide in the presence of a carbodiimide in an organic solvent (e.g. chloroform) at room temperature.